Information Provided By:
Fly News Breaks for March 11, 2019
Mar 11, 2019 | 08:23 EDT
Jefferies analyst Johnny Wong downgraded China Biologic Products Holdings to Underperform from Hold and lowered his price target for the shares to $62 from $67. The company's short-term prospects could have "more potential downside"as the nationwide ancillary drug list could drastically cut sales of placenta polypeptide while increasing selling expenses, Wong tells investors in a research note. The analyst sees a "strong possibility" that placenta polypeptide could be included in the nationwide ancillary drug list later this year, which he notes would further affect China Biologic's sales.
News For CBPO From the Last 2 Days
There are no results for your query CBPO